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Game Changers
DIAGNOSIS DIZZY?
Mr L McCadden; Mr N Bailie
Department of ENT, Royal Victoria Hospital, Belfast, BT12 
6BA
The ‘dizziness’ consultation can be one of frustration for 
both patient and doctor. At times, the history is clear and the 
diagnosis evident. However, often this is not the case and 
trying to glean an accurate history and tie in examination 
findings to arrive at a diagnosis is challenging. Management 
varies significantly depending on the cause of the dizziness, 
so a correct diagnosis is crucial. 
Obtaining an accurate history remains the cornerstone of 
diagnosis. However, we have a useful battery of examinations 
to aid in making the diagnosis. Technology has also advanced 
with an effective and user-friendly device for use in the 
outpatient clinic. Traditional vestibular testing involved 
returning to the department on a different day to see the 
specialist Audiologist for Electronystagmography and 
Calorics testing. These provide limited information about 
vestibular function and the time, cost and patient disruption 
they cause are not insignificant. This new technology is VHIT 
(video head impulse testing). It is a simple device worn like a 
pair of glasses. Sophisticated hardware and software detects 
the eye movements on head impulse testing and this gives 
accurate information on the function of all six semicircular 
canals. This information is immediately available to the ENT 
doctor and aids diagnosis. This has proven a Game Changer 
for the ENT dizziness consultation and allows a diagnosis 
to be made on the first outpatient attendance, which in turn 
leads to earlier treatment intervention and fewer review 
consultations.1
1. Yung et al. Consultant-led, multidisciplinary balance clinic: process 
evaluation of a specialist model of care in a district general hospital 
Clin. Otolaryngol. 2014, 39, 95–101
CAN WE PREVENT PSYCHOSIS? INNOVATIVE 
SERVICE OFFERS NEW HOPE 
Dr C Mulholland, Dr D Mongan, Dr A Boyd, Dr C Shannon 
Holywell Hospital, Steeple Road, Antrim, BT41 2RJ
Schizophrenia is one of the top ten causes of disability 
globally.1 Recent attention has focused on the importance of 
early intervention and prevention, and the identification of 
the prodromal or pre-psychotic phase. Clinical characteristics 
which define those at increased risk of psychosis (an ‘At Risk 
Mental State’ or ARMS) have been explored. These include 
attenuated psychotic symptoms (such as mumbling sounds), 
brief limited intermittent psychotic episodes (BLIPS) where 
definite psychotic symptoms last for less than one week, and 
trait vulnerability (a first-degree relative with psychosis or 
personal history of schizotypal personality disorder) plus 
impairment of social functioning.2 The risk of transition for 
those who meet these criteria is 18% at 6 months and 36% 
at 3 years (meta-analysis; n=2500).3 Research suggests that 
effective treatments are available; cognitive-behavioural 
therapy reduced the rate of transition at 12 months.4 
The STEP (Service, Treatment, Education and Prevention) 
Team is an initiative for young people aged 16 to 35 years 
in the Northern Health and Social Care Trust. This is the 
only bespoke psychosis prevention service in Northern 
Ireland and one of only a handful in the UK.  Intervention 
includes a variety of methods, including one-to-one and 
group-based psychological therapies, and considers the need 
for medication on an individual basis. The STEP Team is 
representative of a new paradigm in mental health service 
provision. By intervening early in order to prevent psychosis 
from developing or progressing much of the associated 
disability can be reduced with obvious benefits for the 
individual and society.
1. WHO. Burden of Mental and Behavioural Disorders. Mental health: 
new understanding, new hope. World Health Organisation, Geneva, 
2001;19-45.
2. The psychosis high-risk state: a comprehensive state-of-the-art review. 
Fusar-Poli P, Borgwardt S, Beechdolf A et al. JAMA Psychiatry. 2013 
January;70(1):107–120.
3. Fusar-Poli P, Bonoldi I, Yung AR et al. Predicting psychosis: meta-
analysis of transition outcomes in individuals at high clinical risk. Arch 
Gen Psychiatry 2012;69(3):220–229.
4. Stafford MR, Jackson H, Mayo-Wilson E et al. Early interventions 
to prevent psychosis: systematic review and meta-analysis.  BMJ 
2013;346:f185. 
THE SUCCESS OF INTRAVITREAL INJECTIONS 
Mr Matthew O’Donnell, Dr Michael Williams 
Centre for Medical Education, QUB, Mulhouse Building, 
RVH, BT12 6BJ
Age-related macular degeneration (AMD) is the leading 
cause of visual loss in those over 65 years of age in the 
developed world. Advanced AMD consists of two forms, dry 
(geographic atrophy or GA) and wet (neovascular AMD): 
both can coexist. It is increasingly considered that dry 
AMD may be the default pathway of ageing. While there is 
currently no medical treatment for dry AMD, wet AMD can 
be treated using regular intravitreal injections of anti-vascular 
endothelial growth factor antibodies (anti-VEGFs) such as 
ranibizumab and aflibercept. Such treatment preserves visual 
acuity in most patients by preventing scarring.
Excess VEGF inhibition may contribute to GA. In the 
Comparison of AMD Treatment Trial (CATT) 1185 
participants with wet AMD were treated with anti-VEGFs. 
For the 1011 with no GA at baseline, the cumulative 
incidence of GA was 17% at 2 years.1  It’s not clear if this 
was associated with the pathological progress of AMD, 
or was an effect of intravitreal anti-VEGFS or was part of 
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normal ageing. Animal models indicate a physiological 
role for VEGF secreted by the retinal pigment epithelium 
in the maintenance of choriocapillaris health, crucial for 
outer retinal function.2  However interesting the debate may 
be, the benefits of anti-VEGFs for most patients should be 
remembered. In the CATT and in the Inhibition of VEGF 
in Age-related choroidal Neovascularisation (IVAN) trial,3 
both trials comparing anti-VEGF drugs and regimens for wet 
AMD, the overall mean visual acuity gain after two years of 
anti-VEGFs was an impressive three lines of vision on the 
visual acuity charts used.1,3  The advent of anti-VEGFs in 
ophthalmology 10 years ago led to a paradigm shift in the 
treatment of many retinal diseases, transforming outcomes for 
patients. Patient centered treatment is an ideal approach, but 
the present challenge is to optimise regimens for wet AMD 
for the large number of patients requiring treatment.
1. Grunwald et al. Incidence and Growth of Geographic Atrophy during 5 
Years of Comparison of Age-Related Macular Degeneration Treatments 
Trials. Ophthalmology. 2017 Jan;124(1):97-104.
2. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D’Amore PA. 
An essential role for RPE-derived soluble VEGF in the maintenance of the 
choriocapillaris. Proc Natl Acad Sci U S A 2009 Nov 3;106(44):18751-
18756.
3. Chakravarthy U et al. Alternative treatments to inhibit VEGF in age-
related choroidal neovascularisation: 2-year findings of the IVAN 
randomised controlled trial. Lancet 2013;382(9900):1258-674.
